Study guide
Clinical Trials, Research Protocols, and Informed Participation
OCN Oncology Certified Nurse Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: OCN Exam Orientation and Official Source Control
Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness
2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care
Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures
3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment
Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation
4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards
Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development
5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy
Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation
6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents
Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation
7 Chapter 7: Symptom Management and Supportive Care
Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination
8 Chapter 8: Oncologic Emergencies and Rapid Escalation
Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage
9 Chapter 9: Psychosocial Dimensions of Oncology Care
Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals
10 Chapter 10: Mixed OCN Case Labs
New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab
11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness
Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning
Clinical Trials, Research Protocols, and Informed Participation
Key Takeaways Explain This Topic AI
Clinical trials answer structured questions across phases 0 through IV about safety, dosing, efficacy, prevention, and supportive care.
Protocol adherence protects participant safety and data integrity; deviations, adverse events, and eligibility concerns require timely reporting.
Informed consent is an ongoing process, not a one-time signature, and participants may withdraw at any time without losing standard care.
Institutional Review Board (IRB) oversight and the Belmont principles of respect, beneficence, and justice govern human-subjects research.
Serious adverse events, including any hospitalization, commonly trigger urgent reporting regardless of expectedness or relatedness.
Last updated: June 2026
- Clinical Trials, Research Protocols, and Informed Participation
- Why Trials Are Central to Oncology
Modern oncology advances because clinical trials test prevention, screening, treatment, symptom management, survivorship, and palliative approaches. The OCN does not design trials but must understand their structure well enough to protect patients and recognize protocol-relevant findings. Trial participation offers access to promising therapy and structured monitoring, but it adds visits, procedures, uncertainty, and strict requirements. Roughly only a small minority of adult cancer patients enroll in trials, so equitable access is itself a quality goal.
Trial Phases and Purposes
- Phase Main purpose Typical size Nursing focus
- Phase 0 Microdosing, pharmacodynamics Very small Teach limited direct benefit
Phase I Safety, maximum tolerated dose, dose-limiting toxicity 15-50 Intensive toxicity assessment, rapid reporting
Phase II Preliminary efficacy and further safety Up to ~100 Response-assessment timing, adverse-event capture
Phase III Compare with standard of care, often randomized Hundreds to thousands Randomization education, adherence support
- Phase IV Postmarketing safety and effectiveness Large, real-world Long-term monitoring, late safety signals
- Ethical and Regulatory Framework
Human-subjects research is governed by the Belmont Report principles: respect for persons (autonomy and informed consent), beneficence (maximize benefit, minimize harm), and justice (fair selection and access). The Institutional Review Board (IRB) reviews and approves protocols, consent documents, and amendments, and can halt a study for safety. A Data and Safety Monitoring Board (DSMB) independently reviews accumulating outcomes and may stop a trial early for harm, futility, or overwhelming benefit. Good Clinical Practice (GCP) standards apply throughout. Knowing who holds oversight tells the nurse where concerns are routed.
Protocol Literacy
A research protocol defines eligibility, intervention, schedule, assessments, dose modifications, prohibited medications, stopping rules, adverse-event reporting, and data collection. The details are not optional. A missed lab draw, an undocumented over-the-counter supplement, an unreported outside hospitalization, a delayed scan, or unplanned steroid exposure can harm the participant and invalidate the data. The OCN must know where to find the protocol, who the study coordinator is, and which findings demand immediate notification.
Eligibility criteria protect participants and sharpen the research question. Inclusion criteria may specify diagnosis, stage, biomarker, prior therapy, organ function, measurable disease, and performance status (often ECOG 0-1 or 0-2). Exclusion criteria may include active infection, pregnancy, uncontrolled autoimmune disease, recent surgery, untreated brain metastases, or prohibited drugs. Nurses often surface eligibility issues during medication reconciliation, symptom review, and lab-trend checks.
Informed Participation
Informed consent includes purpose, procedures, risks, benefits, alternatives (including standard treatment and no treatment), costs, confidentiality, voluntariness, withdrawal rights, and contacts. A provider or delegated qualified research professional obtains consent per policy. The nurse reinforces understanding, assesses for questions, screens for language and literacy barriers, and avoids coercive language. A patient may decline or withdraw and still receive appropriate standard care.
Randomization is the most misunderstood concept. Patients may think the team picks the best arm for them or that randomization means a placebo with no treatment. The nurse explains that, when the protocol randomizes, assignment is by chance, that oncology trials usually compare a new approach against the current standard rather than against nothing, and that the consent document describes each arm.
Safety Monitoring and Adverse-Event Reporting
Research reporting is broader than routine clinical messaging. A serious adverse event (SAE) is one that is fatal, life-threatening, requires or prolongs hospitalization, causes persistent disability, or is a congenital anomaly — and any of these must be reported even if it seems unrelated to the study drug. The nurse documents onset, CTCAE grade when trained, associated symptoms, actions taken, medications used, and impact on activities of daily living. Expected toxicity does not remove the duty to report.
Escalate fever, hypotension, hypoxia, neurologic change, severe diarrhea, uncontrolled vomiting, bleeding, chest pain, dyspnea, severe rash, seizure, tumor-lysis indicators, and any protocol-specified change.
Trial Designs the OCN Should Recognize
Beyond the classic phase structure, modern oncology uses adaptive designs that change patient teaching. Basket trials enroll patients with the same biomarker across different cancer types (for example, an NTRK fusion in any tumor). Umbrella trials enroll one cancer type and assign patients to arms by biomarker. Randomized controlled trials may use a control arm of standard therapy, and placebo in oncology is usually added to standard care rather than replacing it.
The nurse uses these distinctions to correct the common fear that a patient might receive "nothing." Blinding (single or double) means the patient, and sometimes the team, does not know the assignment; the nurse explains that unblinding can occur urgently for safety.
Equity and Access
Enrollment is shaped by transportation, lodging, caregiving, work schedule, insurance coverage, language access, disability accommodations, historical mistrust, and financial toxicity . The OCN screens for barriers early, involves social work, requests interpreter services, coordinates schedules, and makes clear that questions are welcome at any time. Historical events such as the Tuskegee study underlie justified mistrust in some communities, so culturally responsive, transparent communication is part of the justice principle in practice and supports more representative enrollment.